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A B S T R A C T
Background
This is an updated version of a Cochrane review first published in Issue 1, 2010 of The Cochrane Library. In many clinical areas,
integrated care pathways are utilised as structured multidisciplinary care plans that detail essential steps in caring for patients with
specific clinical problems. In particular, care pathways for the dying have been developed as a model to improve care of patients who
are in the last days of life. The care pathways were designed with an aim of ensuring that the most appropriate management occurs
at the most appropriate time and that it is provided by the most appropriate health professional. There have been sustained concerns
about the safety of implementing end-of-life care pathways, particularly in the UK. Therefore, there is a significant need for clinicians
and policy makers to be informed about the effects of end-of-life care pathways with a systematic review.
Objectives
To assess the effects of end-of-life care pathways, compared with usual care (no pathway) or with care guided by another end-of-life
care pathway across all healthcare settings (e.g. hospitals, residential aged care facilities, community).
In particular, we aimed to assess the effects on symptom severity and quality of life of people who are dying; those related to the care
such as families, carers and health professionals; or a combination of these.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 6, 2013), MEDLINE, EMBASE, PsycINFO,
CINAHL, review articles and reference lists of relevant articles. We conducted the original search in September 2009, and the updated
search in June 2013.
Selection criteria
All randomised controlled trials (RCTs), quasi-randomised trial or high-quality controlled before-and-after studies comparing use versus
non-use of an end-of-life care pathway in caring for the dying.
Data collection and analysis
Two review authors assessed the results of the searches against the predetermined criteria for inclusion.
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Main results
The original review identified 920 titles. The updated search found 2042 potentially relevant titles (including the original 920), but
no additional studies met criteria for inclusion in the review update.
Authors’ conclusions
With sustained concerns about the safety of the pathway implementation and the lack of available evidence on important patient and
relative outcomes, recommendations for the use of end-of-life pathways in caring for the dying cannot be made. Since the last version of
this review, no new studies met criteria for inclusion in the review update. With recently documented concerns related to the potential
adverse effects associated with Liverpool Care Pathway (the most commonly used end-of-life care pathway), we do not recommend
decision making based on indirect or low-quality evidence. All health services using end-of-life care pathways are encouraged to have
their use of the pathway, to date, independently audited. Any subsequent use should be based on carefully documented evaluations.
Large RCTs or other well-designed controlled studies are urgently required for the evaluation of the use of end-of-life care pathways in
caring for dying people in various clinical settings. In future studies, outcome measures should include benefits or harms concerning
the outcomes of interest in this review in relation to patients, families, carers and health professionals.
P L A I N L A N G U A G E S U M M A R Y
End-of-life care pathways for the dying
Background
End-of-life pathways are used for people who are in the last days of their life to guide care, aid decision making and provide efficient
care. This review examined whether using end-of-life care pathways in caring for the dying was effective.
Study characteristics
We searched scientific databases for clinical trials in which the effect of the end-of-life care pathway was compared with a control group
that received usual care or with trials comparing one end-of-life care pathway with another end-of-life care pathway. Participants were
to be patients, carers and families who received care guided by an end-of-life care pathway. There were no restrictions on age of the
patient, diagnosis or setting (hospital, home, nursing home).
Key results
We found no studies fitting our criteria.
Quality of evidence
We could not locate any high-quality controlled studies that could answer this important question; despite concerns about the Liverpool
Care Pathway (the most commonly used end-of-life care pathway). It is important for health services to base their care on high-quality
evidence. Until such evidence is available, the use of end-of-life care pathways should be avoided. Large randomised controlled trials
(where patients are allocated to treatments or groups using a random method) or other well-designed controlled studies are required
for evaluating the use of end-of-life care pathways in caring for dying people in various clinical settings. Future studies should measure
positive as well as negative outcomes for patients, families, carers and health professionals.
B A C K G R O U N D
This is an updated version of a Cochrane review first published in
Issue 1, 2010 of The Cochrane Library (Chan 2010).
Description of the condition
It is well recognised that populations in developed countries are
ageing (United Nations 2002). As populations age, the pattern
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of diseases from which people die also changes (WHO 2004).
With advanced ageing, there is an increased risk of death from
chronic diseases such as cancer and heart failure. For example,
cancer was estimated to account for 7.6 million deaths (12% of
all deaths) worldwide in 2008 (WHO and Cancer Research UK
2012). Therefore, palliative care has been identified as one of the
worldwide public health priorities due to the ageing population
(WHO 2004). While palliative care is concerned with “the qual-
ity of life of patients and families who face life-threatening illness,
by providing pain and symptom relief, spiritual and psychosocial
support fromdiagnosis to the end of life and bereavement” (WHO
2009), end-of-life care focuses on the last days and hours of life
(Lunney 2003). The need to provide high-quality end-of-life care
is essential. The needs of dying people may include, but are not
limited to, knowing when death is coming, understanding what
can be expected, being able to maintain a sense of control and hav-
ing their wishes given preference, having access to information and
excellent care, andhaving access to spiritual and emotional support
as required (Steinhauser 2000; Steinhauser 2001). Quality end-
of-life care may vary from person to person and may be difficult to
define and measure accurately. However, such care should at least
include the following domains: quality of life, physical symptoms,
emotional and cognitive symptoms, advanced care planning, func-
tional status, spirituality, grief and bereavement; satisfaction and
quality of care, as well as carer’s well-being (Mularski 2007).
Obstacles to quality end-of-life care have also been identified and
may include failure to recognise treatment futility, lack of com-
munication among decision makers, no agreement on a course
of end-of-life care and failure to implement a timely end-of-life
plan of care (Travis 2002). In recent years, there has been a va-
riety of initiatives developed worldwide to target such issues by
developing systemic approaches towards end-of-life care. These
initiatives include programmes such as the National End of Life
Care Programme (Department of Health 2008), Gold Standards
Framework inCareHomes (Badger 2007), and the Liverpool Care
Pathway (Ellershaw 1997; Ellershaw 2003a).
Description of the intervention
Integrated care pathways are documents that outline the essen-
tial steps of multidisciplinary care in addressing a specific clinical
problem. They can be used to introduce clinical guidelines and
systematic audits of clinical practice (Hockley 2005). The Liver-
pool Care Pathway is an example of an integrated care pathway
specifically for the dying phase of palliation.
Historically, dying patients receiving general hospital care tended
to lack adequate attention from senior medical staff and nurs-
ing staff (Mills 1994). The quality of symptom control and basic
nursing care were considered to be inadequate (Mills 1994). It
was thought that much could be learned from the way patients
were cared for in the hospice movement (Mills 1994). The Liv-
erpool Care Pathway was an example of strategies developed by
the Royal Liverpool University Trust UK) and the Marie Curie
Centre Liverpool (UK) (Ellershaw 1997; Ellershaw 2003a) based
on the care received by people in the hospice setting. Other ob-
jectives of the pathway were to promote cost-effective health care
by appropriate prescribing, and avoiding crisis interventions and
inappropriate hospital admissions. The document is patient-cen-
tred and focuses on the holistic needs of people who are dying. It
incorporates the physical, psychological, social, spiritual and reli-
gious aspects of care (Ellershaw 2007). The Liverpool Care Path-
way defines 19 goals considered essential in the management of
dying patients and for the care of their relatives/carers after death
(Ellershaw 1997; Ellershaw 2003a). These goals were established
with the issues identified from surveys, focus groups, expert opin-
ion and consensus best practice.
Later, several other groups developed care pathways for dying peo-
ple based on the concept of Ellershaw and colleagues (Bookbinder
2005; Fowell 2002; Pooler 2003). While the professional conjec-
ture is that end-of-life care pathways promote best possible patient
outcomes (Ellershaw2007), speculation has suggested possible ad-
verse effects. These controversies included premature use of the
pathway leading to death due to the premature diagnosis of immi-
nent death, the care pathway masking the signs in improvement
in patients and causing carers’ dissatisfaction (Delvin 2009; Smith
2009). There have been substantial concerns raised by the public
and by health professionals that have been documented in the UK
Government-commissioned, independent review of the Liverpool
Care Pathway led by Baroness Julia Neuberger (Neuberger 2013).
The panel reviewed multiple sources including: written submis-
sions from the public and health professionals with experience of
the Liverpool Care Pathway, the academic literature and hospital
complaints. The panel concluded that the Liverpool Care Path-
way, used generically for all patients in the last hours or days of
life, was the wrong approach (Neuberger 2013). The report also
highlighted the complexity around the use of the pathway, specifi-
cally highlighting a number of ethical, safety, clinical practice and
negligence issues and how inadequately dying is diagnosed in clin-
ical care (Neuberger 2013). As a result of the review in July 2013,
the UK government made a decision to phase out the pathway
nationally over the next six to 12 months after the release date of
the Neuberger 2013 review.
It is particularly important to recognise that an end-of-life care
pathway is a complex intervention (McConnell 2013; Medical
Research Council 2000). Although there are methodological con-
siderations and challenges, it is still important to conduct as rig-
orous evaluation as possible to determine the effects (benefits or
harms) of the end-of-life care pathways (Currow 2011; Medical
Research Council 2000). Therefore, a systematic review is war-
ranted to substantiate claims as to whether the end-of-life care
pathways are beneficial or harmful for dying patients and their
carers.
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How the intervention might work
In many clinical areas, integrated care pathways are utilised as
structured multidisciplinary care plans that detail essential steps
in caring for patients with specific clinical problems (Campbell
1998).Care pathways for the dyinghave beendeveloped as amodel
to improve the end-of-life care of all patients. They ensure that the
most appropriatemanagement occurs at themost appropriate time
and that it is provided by themost appropriate health professional.
Why it is important to do this review
Two systematic reviews reported that clinical pathways enhance
efficiency of care without adverse effects on outcomes among pa-
tients who undergo gastrointestinal surgery (Lemmens 2008) and
show a significant length of stay reduction in patients who un-
dergo invasive procedures (Rotter 2008). Both of these systematic
reviews included evidence involving designs such as randomised
controlled trials (RCTs) and other types of controlled studies.
In contrast, one Cochrane systematic review reported that there
was no significant benefit in functional outcome and patient sat-
isfaction, and that quality of life might actually be made worse for
patients following stroke care pathways (Kawn 2004). Therefore,
clinical pathways seem to be beneficial for managing certain clin-
ical problems, but not all.
Clinical pathways for end-of-life care management are used widely
around the world and have been set as a part of the end-of-life
care policies or strategies in some countries (Department ofHealth
2008;Department ofHealth and Ageing 2011;Ministry ofHealth
NZ 2013; National Health Service 2005) There is a significant
need for clinicians to be informed about the utilisation of end-of-
life care pathways with a systematic review.
O B J E C T I V E S
To assess the effects of end-of-life care pathways, compared with
usual care (no pathway) or with care guided by another end-of-
life care pathway across all healthcare settings (e.g. hospitals, resi-
dential aged care facilities, community).
In particular, we aimed to assess the effects on symptom severity
and quality of life of people who are dying; those related to the care
such as families, carers and health professionals; or a combination
of these.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We aimed to include clinical trials in which the effect of the end-
of-life care pathway could be compared with a control group that
received usual care or with trials comparing one end-of-life care
pathway with another end-of-life care pathway. We planned to
include RCTs, cluster RCTs and quasi-RCTs.
If limited RCTs and quasi-RCTs were available, we planned to
consider including controlled before-and-after studies. The review
authors adopted the criteria for inclusion of controlled before-and-
after studies from the Cochrane Effective Practice and Organisa-
tion of Care Review Group guidelines (EPOC 2002). These cri-
teria include (1) contemporaneous data collection, (2) appropri-
ate choice of control site and (3) a minimum of two intervention
sites and two control sites. We did not plan to include any non-
controlled studies (EPOC 2002). The analysis for randomised
and non-randomised studies were to have been undertaken sep-
arately because non-randomised comparisons may overestimate
treatment effects (Chalmers 1983; Sacks 1982), and the size and
direction of the bias can be unpredictable (Deeks 2003).
Types of participants
We included patients and families who had received care guided
by an end-of-life care pathway. We included participants with dif-
ferent diseases such as cancer or organ failure. However, partici-
pants who received interventions must have been receiving care
guided by an end-of-life care pathway for their last days and hours
of life. We applied no restrictions on age of the patient, diagnosis
or setting (hospital, home, nursing home).
Types of interventions
The planned comparisons were:
• intervention (receiving care guided by an end-of-life care
pathway) versus usual care;
• intervention A (pathway A) versus intervention B (pathway
B).
An end-of-life care pathway may have been part of a larger inter-
vention; we only included these studies if the effect of the pathway
could be isolated.
Types of outcome measures
Primary outcomes
• Physical symptom severity (measured by any instrument
used by the study author such as Edmonton Symptom
Assessment Scale (Bruera 1991)), Memorial Symptom
Assessment Scale (Portenoy 1994).
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• Psychological symptom severity (measured by any
instrument used by the study author. For example, Hospital
Anxiety and Depression Scale (Zigmond 1983)).
• Quality of life (measured by any instrument used by the
study author such as McGill Quality of Life Questionnaire
(Cohen 1995)).
• Harms (any adverse effects as determined by the
researchers, health professionals or carers/families).
Secondary outcomes
• Advanced care planning (as measured by whether advanced
care planning had happened or not).
• Communication between healthcare teams and families (as
measured by the occurrence of any family meetings).
• Carer’s well-being.
• Grief and bereavement.
• Patient/staff/carer’s satisfaction.
• Staff confidence.
• Cost of intervention.
• Cost of care.
• Medication/treatment use.
• Spiritual needs.
We planned to include any tools used by the study authors of
the included studies. We would have discussed the validity and
reliability of the tools used in the appraisal of studies.
Search methods for identification of studies
The search was run for the original review in September 2009 and
the subsequent search was run in June 2013.
Electronic searches
We searched:
• the Cochrane Central Register of Controlled Trials
(CENTRAL) up to Issue 6, 2013;
• MEDLINE (1950 to 18 June 2013);
• EMBASE (1980 to 18 June 2013);
• PsycINFO (1980 to 18 June 2013);
• CINAHL (1982 to 18 June 2013).
We developed the search strategy to comprise searches for both
keywords and medical subject headings under existing database
organisational schemes. The strategies for each database are pre-
sented in Appendix 1, Appendix 2, Appendix 3, Appendix 4 and
Appendix 5.We applied no restrictions by language. We translated
foreign language abstracts for the application of the inclusion and
exclusion criteria, and, where necessary, we planned to translate
the methods, results and discussion sections for inclusion in the
review.
Searching other resources
We searched the reference lists of any relevant reviews or other
studies, scanning paper issues of journals relevant to interven-
tions of end-of-life care pathway and scanning abstracts from rel-
evant conference proceedings. We also contacted experts in the
field and would have contacted authors of included studies for
advice as to other relevant studies. We also used Google to search
the World Wide Web, Caresearch (www.caresearch.com.au), the
ProQuest Dissertations and Theses database for grey literature
and conference abstracts. We searched databases in TrialsCentral (
www.trialscentral.org), the World Health Organization’s (WHO)
Clinical Trial Search Portal (www.who.int/trealsearch), and Cur-
rent Controlled Trials (www.controlled-trials.com) to identify on-
going or recently completed studies. We planned, if applicable, to
present relevant ongoing studies in a table in the review.
Data collection and analysis
Selection of studies
Two review authors pre-screened all search results (titles and ab-
stracts) for possible inclusion, and those selected by either or both
review authors were subject to full-text assessment. Two review
authors independently assessed the selected articles for inclusion.
We had planned to resolve any discrepancies by consensus, over-
seen by a third review author acting as arbiter, with approval by
one review author and the arbiter being sufficient. We had also
planned to list those studies excluded after full-text assessment in
the table Characteristics of excluded studies, giving reasons for ex-
clusion.
Data extraction and management
We developed a data extraction form based on the Cochrane
Pain, Palliative and Supportive Care Review Group’s template.We
planned to extract the following main sets of data from each in-
cluded study:
• lead author;
• date;
• study participant inclusion criteria;
• participants (participant diagnoses/condition(s) and
demographics: race/ethnicity, gender, religion/culture,
socioeconomic status, age);
• study design and timetable, randomisation, allocation
concealment;
• interventions (end-of-life care pathway type);
• intervention setting (hospital, home, residential aged care
facilities);
• numbers of participants in each trial arm, withdrawals and
drop-outs;
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• outcome measures; time(s) at which outcomes were
assessed.
At least two review authors were to have independently extracted
data on to the data extraction form. Any discrepancies would have
been referred to a third review author and any errors or inconsis-
tencies resolved. The first review author was to have entered the
data into ReviewManager 5 (RevMan 2012), with another review
author checking accuracy of the data entered.
Assessment of risk of bias in included studies
We intended to assess and report on the risk of bias of included
studies in accordance with the guidelines in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011), which
recommends the explicit reporting of the following individual do-
mains:
The criteria for RCTs were:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessors
(assessed for each main outcome or class of outcome);
• incomplete outcome data (assessed for each main outcome
or class of outcome);
• selective outcome reporting;
• other sources of bias.
The criteria for controlled before-and-after studies were:
• baseline measurement of outcomes;
• baseline characteristics of studies using second site as
control;
• protection against exclusion or selection bias;
• protection against contamination;
• reliable primary outcomes measures;
• appropriate analysis of data.
We would have examined and reported the following:
• validation and reliability of outcome measures;
• whether the study obtained ethics committee approval and
ensured informed consent for participation;
• use of standardised protocols for information delivery. We
were to have checked for consistency of the delivery of
interventions where possible.
Two review authors would have independently assessed the risk
of bias in included studies, with any disagreements resolved by
discussion and consensus, and with a third review author acting
as arbiter. We planned to present our assessment in ’Risk of bias’
tables for each included study. We would have contacted study
authors for additional information about the study methods as
necessary. We would have incorporated the results of the risk of
bias assessment into the review through narrative description and
commentary about each of the items mentioned.
Measures of treatment effect
For individual studies, effect measures for categorical outcomes
were to include risk ratio (RR) with their 95% confidence inter-
vals (CI). For statistically significant effects, we would have cal-
culated number needed to treat for an additional beneficial effect
(NNTB). If possible, for continuous outcomes, the effect mea-
sure was to have been mean difference (MD) or, if the scale of
measurement differed across trials, standardised mean difference
(SMD), each with its 95% CI. For meta-analyses (see below), for
categorical outcomes, we would have calculated typical estimates
of RRwith their 95%CI; and for continuous outcomes, we would
have calculated the mean difference (MD) or a summary estimate
for SMD, each with its 95% CI.
We would have analysed data using The Cochrane Collaboration’s
Review Manager 5 software (RevMan 2012).
Unit of analysis issues
We would have checked unit of analysis issues if we had found
cluster randomised trials.Wedidnot expect to find cross-over trials
for this type of intervention due to the end-of-life pathway nature.
If cluster randomised trials had been identified, we would have
reported the intracluster correlation coefficient and adjusted for
clustering if possible. Alternatively, we would have presented the
cluster randomised studies as point estimates of the intervention
effect without any statistical analysis or CIs.
Dealing with missing data
If some outcome data remained missing despite our attempts to
obtain complete outcome data from authors, we would have per-
formed an available-case analysis, based on the numbers of par-
ticipants for whom outcome data were known. If standard devia-
tions (SD) were missing, we would have imputed them from other
studies, or where possible, computed them from standard errors
(SE) using the formula SD = SE x
√
N, where these were available
(Higgins 2011). We also planned to report on levels of drop-outs
in the intervention and comparison groups as an indicator of ’ac-
ceptability’ of the intervention, and the likelihood of bias.
Assessment of heterogeneity
We would have tested heterogeneity using the Chi2 statistics and
any heterogeneity was to have been further quantified with the
I2 statistic (which describes the percentage of the variability in
effect estimates that is due to heterogeneity rather than sampling
error). We would have considered a value greater than 50% as
representing substantial heterogeneity (Higgins 2011).
Assessment of reporting biases
Wewouldhave assessed reporting bias using guidelines inCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
6End-of-life care pathways for improving outcomes in caring for the dying (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We did not expect to find a large number of studies, so we thought
it was unlikely that publication or inclusion bias would be assessed.
However, we planned to do a funnel plot if enough studies were
available to do a meaningful assessment of publication bias.
Data synthesis
If studies had been sufficiently similar in terms of population, in-
clusion criteria, interventions, outcomes (including the time(s) at
which these are assessed), or a combination of these, we would
have considered pooling the data statistically using meta-analysis.
We would have reported the results of the individual trials sepa-
rately where the outcome data were unsuitable for meta-analysis.
We planned to use fixed-effect models when population measures
were similar and random-effects models where population param-
eters varied from study to study.
Subgroup analysis and investigation of heterogeneity
We would have conducted subgroup analyses if sufficient data
could support the analyses. Subgroups may have included disease
types and settings where care was received.
Sensitivity analysis
If there were other sources of heterogeneity, we planned to explore
further by using sensitivity analysis to determine the effects of the
end-of-life care pathways, overall methodological quality and use
of intention-to-treat analysis.Wewould have removed studies with
high attrition rates (over 50%) from themeta-analysis to determine
whether the results would be significantly different without them.
R E S U L T S
Description of studies
See: ’Characteristics of included studies’; ’Characteristics of
excluded studies’; ’Characteristics of ongoing studies’.
Results of the search
We found and assessed 2042 titles and abstracts in electronic for-
mat (including the 920 retrieved for the original review).
Included studies
We found no studies fulfilling the study eligibility criteria.
Excluded studies
We excluded 28 studies in the original review and 32 in the update
because the study designs did not meet the criteria for included
studies. We excluded three controlled before-and-after studies be-
cause they did not meet the minimum criteria to be included in
this review. These criteria include (1) contemporaneous data col-
lection, (2) appropriate choice of control site and (3) a minimum
of two intervention sites and two control sites (EPOC 2002).
Risk of bias in included studies
We found no included studies, so could not evaluate bias.
Effects of interventions
We found no included studies.
D I S C U S S I O N
In this update, we identified no new RCTs, quasi-experimental
studies or controlled before-and-after studies meeting our eligi-
bility criteria for this review. Although the UK government has
made a decision to phase out the Liverpool Care Pathway (the
most commonly used end-of-life care pathway) in the UK, such
decisions have not been made in other countries. With a number
of safety concerns reported by Neuberger’s report and the lack of
evidence (Neuberger 2013), it is extremely difficult to determine
whether the suggested negative consequences associated with the
Liverpool Care Pathway are associated with the actual pathway-
based care; poor implementation of pathway-based care; the emo-
tional consequences of illness, death and bereavement; or a combi-
nation of these (Parry 2013). There is an urgent need for rigorous
research to answer several key questions: do the adverse findings
from Neuberger’s report apply to countries other than the UK
and, if so, to what extent? What are the differences in outcomes
between the Liverpool Care Pathway and other end-of-life care
pathways? Are the outcomes for dying patients who are placed on
an end-of-life care pathway different to those receiving usual care?
If the answers to these questions are ’yes’: are the right people put
on the end-of-life care pathway at the right time in their illness
trajectory? In which settings should an end-of-life care pathway be
used? How senior should the clinicians be and how much history
of this patient should they have before an end-of-life care pathway
is initiated?
The results of a number of case series andnon-eligible controlled or
non-controlled before-and-after studies indicated that end-of-life
care pathways may have the potential to improve symptom man-
agement (Bailey 2005; Veerbeek 2008); clinical documentation
and assessment (Bookbinder 2005; Luhrs 2005; Veerbeek 2008);
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knowledge of end-of-life care among internal medicine students
(Okon 2004); prescription of medications for end-of-life (Bailey
2005; Mirando 2005); bereavement levels of relatives (Veerbeek
2008a); and outcomes in relation to respect, kindness, dignity,
family emotional support, family self efficacy and co-ordination
of care (Costantini 2013a). However, the effects of pathways are
difficult to ascertain from these designs. Moreover, none of the
excluded studies reported the adverse effects of any end-of-life care
pathway.
It is well accepted that designing and conducting trials involv-
ing the dying is difficult and challenging due to methodological
and ethical issues (Fowell 2004; Karlawish 2003). These issues
may include difficult patient recruitment due to the patient being
too ill to participate or unable to give informed consent, or the
heterogeneous nature of palliative populations (Addington-Hall
2007). However, researchers should attempt to investigate end-
of-life interventions with the most rigorous research methodol-
ogy possible. For example, cluster randomised trials across multi-
ple centres may be considered. One feasibility study revealed that
cluster randomised trials are possible and may be more effective
in recruiting patients in this population than randomised consent
(Fowell 2006). Randomised consent requires informed consent
after randomisation, but only if the patient is to receive the ex-
perimental treatment (Zelen 1990). Moreover, a range of other
strategies can also be considered to make clinical trials possible.
These include designing a shorter term study, limiting the number
of outcomes, undertaking frequent follow-ups, advanced consent
and proxy consent where appropriate for studies involving this
population (Reyna 2008). Although the challenges in conducting
clinical research for the dying are well recognised (Constantini
2011), one Italian research team acknowledges the importance of
generating high-quality evidence to inform practice in this area
and has completed a phase III cluster RCT to test the effective-
ness of the Liverpool Care Pathway (Costantini 2013a). However,
at the time of this update being finalised, the final report of the
Costantini 2013a trial had not been published.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although strong evidence supporting end-of-life care pathways is
lacking, the principles underpinning such pathways remain rele-
vant. Plans for end-of-life care should be developed in open con-
sultation with the patient and significant others. All health services
using an end-of-life care pathway are encouraged to have their use
of the pathway, to date, independently audited, with particular
emphasis on theNeuberger’s findings (Neuberger 2013). Any sub-
sequent use should be based on carefully documented prospective
evaluations.
Implications for research
Although high-level evidence is currently unavailable, existing re-
search may be used to inform the development of any future tri-
als. There remains an urgent need for large RCTs or other well-
designed controlled studies for the evaluation of the use of end-
of-life care pathways in caring for dying people. Such evaluations
might be difficult in countries where end-of-life care pathways
are embedded in practice or are being withdrawn. However, it re-
mains important to test the effectiveness of end-of-life care path-
ways where possible. To ensure generalisability, such trials should
stratify participants according to different care settings includ-
ing general acute care setting, emergency department, cancer care
units, residential aged care facilities and specialist palliative care
units. Additionally, if such studies demonstrate positive effects, it
is imperative that there is careful ongoing evaluation of the im-
plementation of any revised pathway as it is made available more
broadly. In future studies, outcome measures should include the
outcomes of interest in this review in relation to patients, families,
carers and health professionals. These may include patients’ symp-
tom control, harms, communication between healthcare team and
families, carer’s well-being, grief and bereavement, staff and carers’
satisfaction, staff confidence, cost of intervention, cost of care and
medication use. Further, investigations of the effects of such path-
ways for specific populations are warranted. These specific popu-
lations may include, but are not limited to, children and patients
with end-stage organ failure or dementia.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bailey 2005 Before and after study (without control)
Bookbinder 2005 Controlled before-and-after study: non-contemporaneous data collection, non-comparable sampling
Chaplin 2009 Non-experimental study: case report
Costantini 2013a Before-and-after study (without control)
Di Leo 2013 Non-experimental study: implementation phase 0-1 study (without control)
Ellershaw 1997 Non-experimental study: case report
Ellershaw 2001 Non-experimental study: audit
Ellershaw 2003 Review
Ellershaw 2007 Letter
Fowell 2002 Non-experimental study: audit
Fowell 2003 Non-experimental study: audit
Hardy 2007 Non-experimental study: audit
Hockley 2005 Non-experimental study: qualitative study
Horey 2012 Non-experimental study
Jack 2003 Non-experimental study: qualitative study/focus groups
Johnson 2004 Non-experimental study: cross-sectional survey study
Luhrs 2005 Controlled before-and-after study: non-contemporaneous data collection, non-comparable sampling and
does not have at least 2 intervention and 2 control sites
Main 2006 Non-experimental study: case report
Matthews 2006 Non-experimental study: audit
Mellor 2004 Qualitative study
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(Continued)
Mirando 2005 Non-experimental study: audit
Neo 2012 Non-experimental study: retrospective audit
Okon 2004 Controlled before-and-after study: does not have at least 2 intervention and 2 control sites
Osterlind 2008 Non-experimental study: qualitative study
Peterson 2000 Non-experimental study: case report
Pooler 2003 Non-experimental study: audit
Rose 2006 Non-experimental study: audit
Taylor 2007 Before-and-after study (without control)
Thompson-Hill 2009 Before-and-after study (without control)
Veerbeek 2006 Non-experimental study: audit
Veerbeek 2008 Before-and-after study (without control)
Veerbeek 2008a Before-and-after study (without control)
Characteristics of studies awaiting assessment [ordered by study ID]
Costantini 2013
Methods This is a randomised cluster trial, stratified by regions and matched for assessment period. Pairs of eligible medical
wards from different hospitals will be randomised to receive the LCP-I programme or no intervention until the end
of the trial. The LCP-I programme will be implemented by a PCU
Participants Participants are pairs of medical wards from different hospitals, that fulfil the eligibility criteria
Inclusion criteria:
• classified in the regional records as ’Medical’, ’General Medical’ or ’Internal Medical’
• at least 25 cancer deaths on the ward per year. The data can be estimated from a review of deaths occurring on
the ward over a minimum 6-month period during the 2 years preceding the start of the trial
• consent from the hospital management to participate to the trial
• consent from the head of the medical ward to participate to the trial
• consent from an expert and skills-trained PCU to implement the LCP-I programme
Exclusion criteria:
• if in the same hospital another medical ward has already been randomly selected to participate in the research
programme (regardless of which arm was randomised)
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Costantini 2013 (Continued)
Interventions The LCP-I programme: a continuous quality improvement programme of end-of-life care implemented by a PCU in
a hospital medical ward. The programme is a complex intervention involving implementation project on the ward,
induction of the programme, intensive education programme, clinical implementation of the LCP-I documentation
with intensive support to the ward staff, evaluation and further training and consolidation exercises
Outcomes Primary outcomes:
The quality of end-of-life care:
• the Global Scale of the “Toolkit After-death Bereaved Family Member Interview” (Teno 2001)
• the Global Scale of the Toolkit is a combination of 6 items that are evaluated at the end of the interview on a
0-10 scale (see page 15 of the Toolkit). The scores of the 6 items are added up and linearised on a 0-100 scale where
0 = poor quality and 100 = high quality of care. Where answers are missing for 1 or more of the 6 items, the score is
estimated for the item for which valid answers are available. To calculate the score on the Global Scale a minimum
of 4 valid answers out of 6 are necessary
The quality of the end-of-life care provided to dying patients:
• the Global Scale of the Toolkit, as expressed on a 0-100 scale where 0 = poor quality and 100 = excellent
quality of care
Notes Trial registration: ClinicalTrials.gov Identifier: NCT01081899
LCP-I: Liverpool Care Pathway - Italian; PCU: palliative care unit.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Palliative Care] this term only
#2 palliat*
#3 end-of-life
#4 terminally ill
#5 MeSH descriptor: [Terminally Ill] this term only
#6 dying
#7 hospice
#8 MeSH descriptor: [Hospices] explode all trees
#9 end-stage
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 MeSH descriptor: [Critical Pathways] this term only
#12 ((clinical or critical or care) next path*)
#13 (care next (map* or plan*))
#14 MeSH descriptor: [Guideline] explode all trees
#15 MeSH descriptor: [Health Planning Guidelines] this term only
#16 MeSH descriptor: [Guideline Adherence] this term only
#17 (compliance next (protocol* or policy or guideline*))
#18 (guideline* near/2 (introduc* or issu* or impact or effect* or disseminat* or distribut* or implement*))
#19 “nursing protocol*”
#20 “professional standard*”
#21 (practice guidelin* or practice protocol* or clinical practice guidelin*)
#22 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 #10 and #22
Appendix 2. MEDLINE and MEDLINE In-progress (Ovid) search strategy
Database: Ovid MEDLINE(R)
1 Palliative Care/ or palliat$.mp.
2 end-of-life.mp.
3 terminally ill.mp. or Terminally Ill/
4 dying.mp.
5 hospice.mp. or Hospices/
6 end-stage.mp.
7 or/1-6
8 Critical Pathways/
9 ((clinical or critical or care) adj path$).mp.
10 (care adj (map$ or plan$)).mp.
11 exp Guideline/
12 Health Planning Guidelines/
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13 Guideline Adherence/
14 (compliance adj (protocol? or policy or guideline?)).mp.
15 (guideline? adj2 (introduc$ or issu$ or impact or effect? or disseminat$ or distribut$ or implement$)).mp.
16 nursing protocol?.mp.
17 professional standard$.mp.
18 (practice guidelin$ or practice protocol$ or clinical practice guidelin$).mp.
19 or/8-18
20 Guideline.pt.
21 randomized controlled trial.pt.
22 controlled clinical trial.pt.
23 Intervention Studies/
24 experiment$.mp.
25 (time adj series).mp.
26 (pre test or pretest or post test or posttest).mp.
27 Random Allocation/
28 impact.mp.
29 intervention?.mp.
30 Evaluation Studies/
31 Comparative Study.pt.
32 Humans/
33 or/20-31
34 7 and 19 and 32 and 33 (1096)
Appendix 3. EMBASE (Ovid) search strategy
1 Palliative Care/ or palliat$.mp.
2 end-of-life.mp.
3 terminally ill.mp. or Terminally Ill/
4 dying.mp.
5 hospice.mp. or Hospices/
6 end-stage.mp.
7 or/1-6
8 Critical Pathways/
9 ((clinical or critical or care) adj path$).mp.
10 (care adj (map$ or plan$)).mp.
11 exp Practice Guideline/
12 Health Planning Guidelines/
13 Guideline Adherence/
14 (compliance adj (protocol? or policy or guideline?)).mp.
15 (guideline? adj2 (introduc$ or issu$ or impact or effect? or disseminat$ or distribut$ or implement$)).mp.
16 nursing protocol?.mp.
17 professional standard$.mp.
18 (practice guidelin$ or practice protocol$ or clinical practice guidelin$).mp.
19 or/8-18
20 randomized controlled trial/
21 controlled clinical trial/
22 Intervention Studies/
23 experiment$.mp.
24 (time adj series).mp.
25 (pre test or pretest or post test or posttest).mp.
26 Random Allocation/
27 impact.mp.
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28 intervention?.mp.
29 Evaluation Studies/
30 comparative study/
31 Humans/
32 or/20-30
33 7 and 19 and 32 and 31
Appendix 4. PsycINFO (Ovid) search strategy
1 Palliative Care/ or palliat$.mp.
2 end-of-life.mp.
3 terminally ill.mp. or Terminally Ill/
4 dying.mp.
5 hospice.mp. or Hospices/
6 end-stage.mp.
7 or/1-6
8 ((clinical or critical or care) adj path$).mp.
9 (care adj (map$ or plan$)).mp.
10 (compliance adj (protocol? or policy or guideline?)).mp.
11 (guideline? adj2 (introduc$ or issu$ or impact or effect? or disseminat$ or distribut$ or implement$)).mp.
12 nursing protocol?.mp.
13 professional standard$.mp.
14 (practice guidelin$ or practice protocol$ or clinical practice guidelin$).mp.
15 (or/8-9) or (or/10-14)
16 7 and 15
Appendix 5. CINAHL (EBSCO) search strategy
S38 S23 AND S36 AND S37 Search modes - Boolean/Phrase Interface - EBSCOhost
S37 S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 Search modes - Boolean/
Phrase Interface - EBSCOhost
S36 (MH “Human”) Search modes - Boolean/Phrase Interface - EBSCOhost
S35 PT comparative study Search modes - Boolean/Phrase Interface - EBSCOhost
S34 (MH “Evaluation Research”) Search modes - Boolean/Phrase Interface - EBSCOhost
S33 intervention* Search modes - SmartText Searching Interface - EBSCOhost
S32 intervention* Search modes - Boolean/Phrase Interface - EBSCOhost
S31 impact Search modes - Boolean/Phrase Interface - EBSCOhost
S30 (MH “Random Assignment”) Search modes - Boolean/Phrase Interface - EBSCOhost
S29 (pre test or pretest or post test or posttest) Search modes - Boolean/Phrase Interface - EBSCOhost
S28 “time series” Search modes - Boolean/Phrase Interface - EBSCOhost
S27 experiment* Search modes - Boolean/Phrase Interface - EBSCOhost
S26 (MH “Experimental Studies”) Search modes - Boolean/Phrase Interface - EBSCOhost
S25 PT randomized controlled trial Search modes - Boolean/Phrase Interface - EBSCOhost
S24 PT guideline Search modes - Boolean/Phrase Interface - EBSCOhost
S23 S22 Limiters - Published Date from: 20090801-20130131
Search modes - Boolean/Phrase Interface - EBSCOhost
S22 (S10 AND S21) Search modes - Boolean/Phrase Interface - EBSCOhost
S21 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 Search modes - Boolean/Phrase Interface -
EBSCOhost
S20 (“practice guidelin*” or “practice protocol*” or “clinical practice guidelin*”) Searchmodes - Boolean/Phrase Interface - EBSCOhost
S19 “professional standard$” Search modes - Boolean/Phrase Interface - EBSCOhost
S18 “nursing protocol?” Search modes - Boolean/Phrase Interface - EBSCOhost
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S17 (guideline? N2 (introduc* or issu* or impact or effect? or disseminat* or distribut* or implement*)) Search modes - Boolean/Phrase
Interface - EBSCOhost
S16 (compliance N1 (protocol? or policy or guideline?)) Search modes - Boolean/Phrase Interface - EBSCOhost
S15 (MH “Guideline Adherence”) Search modes - Boolean/Phrase Interface - EBSCOhost
S14 (MH “Practice Guidelines”) Search modes - Boolean/Phrase Interface - EBSCOhost
S13 “care map*” or “care plan*” Search modes - Boolean/Phrase Interface - EBSCOhost
S12 “clinical path*” or “critical path*” or “care path*” Search modes - Boolean/Phrase Interface - EBSCOhost
S11 (MH “Critical Path”) Search modes - Boolean/Phrase Interface - EBSCOhost
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 Search modes - Boolean/Phrase Interface - EBSCOhost
S9 end-stage Search modes - Boolean/Phrase Interface - EBSCOhost
S8 (MH “Hospices”) Search modes - Boolean/Phrase Interface - EBSCOhost
S7 hospice Search modes - Boolean/Phrase Interface - EBSCOhost
S6 dying Search modes - Boolean/Phrase Interface - EBSCOhost
S5 (MH “Terminally Ill Patients”) Search modes - Boolean/Phrase Interface - EBSCOhost
S4 “terminally ill” Search modes - Boolean/Phrase Interface - EBSCOhost
S3 end-of-life Search modes - Boolean/Phrase Interface - EBSCOhost
S2 Palliative Care Search modes - Boolean/Phrase Interface - EBSCOhost
S1 (MH “Palliative Care”) Search modes - Boolean/Phrase Interface - EBSCOhost
WH A T ’ S N E W
Last assessed as up-to-date: 14 November 2013.
Date Event Description
23 August 2013 New search has been performed A new search was run in June 2013 but no new studies
met criteria for inclusion in the review update
15 August 2013 New citation required but conclusions have not changed New Citation: Conclusion not changed
C O N T R I B U T I O N S O F A U T H O R S
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Selecting trials: RC, JW.
Data entry: RC, JW.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Critical Pathways; ∗Terminal Care; Treatment Outcome
MeSH check words
Humans
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